800 TCR
Alternative Names: 800-TCR; anti-HERV-E TCR - T-Cure Bioscience; TCR-800Latest Information Update: 28 Feb 2025
At a glance
- Originator T-Cure
- Developer Immunotech Biopharm; National Heart, Lung and Blood Institute
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Renal cell carcinoma
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for preclinical development in Renal-cell-carcinoma in China (Parenteral, Infusion)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Renal-cell-carcinoma(Metastatic disease) in USA (Parenteral, Infusion)
- 28 Jan 2024 Pharmacodynamics data from a preclinical trial in Renal cell carcinoma released by T-Cure BioScience